At the time of writing, RenovoRx Inc [RNXT] stock is trading at $1.02, down -0.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The RNXT shares have gain 28.95% over the last week, with a monthly amount glided 4.72%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
For the past year, the stock price of RenovoRx Inc fluctuated between $0.75 and $1.69. RenovoRx Inc [NASDAQ: RNXT] shares were valued at $1.02 at the most recent close of the market.
Analyzing the RNXT fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -255.12%, Pretax Profit Margin comes in at -204.98%, and Net Profit Margin reading is -204.98%. To continue investigating profitability, this company’s Return on Assets is posted at -1.09, Equity is -1.56 and Total Capital is -1.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9867 points at the first support level, and at 0.9533 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0467, and for the 2nd resistance point, it is at 1.0733.
Ratios To Look Out For
It is important to note that RenovoRx Inc [NASDAQ:RNXT] has a current ratio of 4.10. As well, the Quick Ratio is 4.10, while the Cash Ratio is 3.75. Considering the valuation of this stock, the price to sales ratio is 931.86, the price to book ratio is 5.47.
Transactions by insiders
Recent insider trading involved Agah Ramtin, Chief Medical Officer, that happened on Apr 15 ’25 when 15000.0 shares were purchased. Chief Executive Officer, Bagai Shaun completed a deal on Apr 15 ’25 to buy 7500.0 shares. Meanwhile, Chief Medical Officer Agah Ramtin bought 20000.0 shares on Apr 11 ’25.
